In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Diverse Teachers Recruitment Act of 
2010''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) Department of Education statistics reveal a lack of 
        diversity among public schoolteachers. During the school year 
        of 2007 through 2008, an estimated 83.1 percent of public 
        schoolteachers were Caucasian, while 7.1 percent were Latino, 7 
        percent were African-American, and 1.2 percent were Asian. Of 
        all public schoolteachers, 24.1 percent were male and 75.9 
        percent were female.
            (2) Some experts believe the lack of diversity can leave 
        students in underrepresented groups without role models to whom 
        they can relate, which may lead to poorer performance in the 
        classroom. Statistics show that students in some 
        underrepresented groups have lower standardized test scores and 
        lower graduation rates.
            (3) Teacher demographics should better reflect those of the 
        population as a whole, ensuring that students have role models 
        from diverse backgrounds and racial and ethnic groups and of 
        different genders.

SEC. 3. RECRUITMENT, TRAINING, AND RETENTION OF TEACHERS FROM 
              UNDERREPRESENTED GROUPS.

    (a) In General.--Title II of the Elementary and Secondary Education 
Act of 1965 (20 U.S.C. 6601 et seq.) is amended by adding at the end 
the following new part:

    ``PART E--RECRUITMENT, TRAINING, AND RETENTION OF TEACHERS FROM 
                        UNDERREPRESENTED GROUPS

``SEC. 2501. GRANT PROGRAM.

    ``(a) Authorization.--From amounts appropriated under section 2505, 
the Secretary shall make grants on a competitive basis to eligible 
entities for recruiting, training, and retaining individuals from 
underrepresented groups as teachers at public elementary schools and 
secondary schools.
    ``(b) Eligibility.--The Secretary may only make a grant under 
subsection (a) to an eligible entity that--
            ``(1) serves schools that have difficulty recruiting, 
        training, and retaining individuals from underrepresented 
        groups as teachers; and
            ``(2) submits an application at such time, in such form, 
        and containing such information and assurances as the Secretary 
        may require, including--
                    ``(A) a description of how the activities the 
                eligible entity carries out with grant funds will 
                ensure the recruitment, training, and retention of a 
                significant number of individuals from underrepresented 
                groups; and
                    ``(B) a description of the difficulty recruiting, 
                training, and retaining individuals from 
                underrepresented groups experienced by the schools 
                served by the eligible entity.
    ``(c) Priority.--In making grants under subsection (a), the 
Secretary shall give priority to--
            ``(1) local educational agencies (or consortia of local 
        educational agencies) that serve the most high-need schools; 
        and
            ``(2) local educational agencies (or consortia of local 
        educational agencies) that serve schools with the highest 
        percentages of minority individuals in their student 
        populations.
    ``(d) Matching Funds.--
            ``(1) In general.--The Secretary may not make a grant to an 
        eligible entity under subsection (a) unless the eligible entity 
        agrees that, with respect to the costs to be incurred by the 
        eligible entity in carrying out the activities for which the 
        grant is awarded, the eligible entity will make available non-
        Federal contributions in an amount equal to not less than 10 
        percent of the Federal funds provided under the grant.
            ``(2) Satisfying matching requirement.--The non-Federal 
        contributions required under paragraph (1) may be--
                    ``(A) in cash or in-kind, including services, 
                fairly evaluated; and
                    ``(B) from--
                            ``(i) any private source; or
                            ``(ii) a State educational agency or local 
                        educational agency.
            ``(3) Waiver.--The Secretary may waive or reduce the non-
        Federal contribution required by paragraph (1) if the eligible 
        entity involved demonstrates that it cannot meet the 
        contribution requirement due to financial hardship.

``SEC. 2502. REPORTS TO SECRETARY.

    ``An eligible entity receiving a grant under section 2501(a) shall 
submit to the Secretary not later than 90 days after the end of each 
school year in which the entity receives grant funds a report that 
contains--
            ``(1) a description of the activities for which the entity 
        used grant funds during such school year;
            ``(2) data concerning, with respect to the schools served 
        by the entity--
                    ``(A) the number of individuals from 
                underrepresented groups that began teaching during such 
                school year;
                    ``(B) the retention rate of teachers who are 
                individuals from underrepresented groups;
                    ``(C) in the case of the report covering the last 
                school year in which the entity receives grant funds, 
                indicators of student academic achievement during such 
                school year as compared with previous school years, 
                disaggregated, if possible, by the achievement of--
                            ``(i) economically disadvantaged students;
                            ``(ii) students from major racial groups;
                            ``(iii) students with disabilities; and
                            ``(iv) students with limited English 
                        proficiency;
                    ``(D) student graduation rates for the school year 
                covered by the report as compared with previous school 
                years, if applicable in the case of the schools served 
                by the entity; and
                    ``(E) student attendance rates for the school year 
                covered by the report as compared with previous school 
                years; and
            ``(3) a description of and data regarding such 
        characteristics of the schools served by the entity, and the 
        students of such schools, as the Secretary considers 
        appropriate, including the number and percentage of students in 
        each of the groups listed in clauses (i) through (iv) of 
        paragraph (2)(C).

``SEC. 2503. BEST PRACTICES INFORMATION CLEARINGHOUSE.

    ``(a) In General.--The Secretary shall evaluate the success of the 
activities carried out by eligible entities using grant funds received 
under section 2501(a) and compile a database of best practices for 
recruiting, training, and retaining individuals from underrepresented 
groups as public elementary and secondary school teachers. The 
Secretary shall make such database available to eligible entities 
(regardless of whether such entities have received grants under such 
section) through an Internet Web site.
    ``(b) Funds Available.--Of the amounts appropriated to carry out 
this part for a fiscal year, the Secretary may use not more than 10 
percent to carry out this section during such fiscal year.

``SEC. 2504. DEFINITIONS.

    ``In this part, the following definitions apply:
            ``(1) Eligible entity.--The term `eligible entity' means--
                    ``(A) a local educational agency (or consortium of 
                local educational agencies); or
                    ``(B) an entity that--
                            ``(i) has entered into a partnership with a 
                        local educational agency (or consortium of 
                        local educational agencies) in which the local 
                        educational agency (or consortium of local 
                        educational agencies) is the primary partner; 
                        and
                            ``(ii) is a private nonprofit organization, 
                        educational service agency, institution of 
                        higher education, or State educational agency.
            ``(2) High-need high school.--The term `high-need high 
        school' means a secondary school--
                    ``(A) in which the entering grade of the school is 
                not lower than grade 9 and that includes grade 12; and
                    ``(B) that has a graduation rate of not more than 
                65 percent in each of the 2 academic years prior to the 
                submission of the grant application.
            ``(3) High-need middle school.--The term `high-need middle 
        school' means a secondary school--
                    ``(A) in which the entering grade is not lower than 
                grade 6 and the highest grade is not higher than grade 
                9; and
                    ``(B) from which not less than 35 percent of the 
                students who complete such school enroll in a high-need 
                high school.
            ``(4) High-need school.--The term `high-need school' means 
        a public school, including a charter school (as such term is 
        defined in section 5210(1))--
                    ``(A) in which not less than 40 percent of the 
                enrolled students are eligible to receive free or 
                reduced price lunches under section 9(b) of the Richard 
                B. Russell National School Lunch Act (42 U.S.C. 
                1758(b)); or
                    ``(B) that is a high-need high school or a high-
                need middle school.
            ``(5) Individual from an underrepresented group.--The term 
        `individual from an underrepresented group' means an individual 
        who is a member of a racial group or gender that has 
        historically been underrepresented among teachers in public 
        primary and secondary schools in the United States.
            ``(6) Minority individual.--The term `minority individual' 
        means an individual who is a member of a racial group that has 
        historically been underrepresented among teachers in public 
        primary and secondary schools in the United States.

``SEC. 2505. AUTHORIZATION OF APPROPRIATIONS.

    ``There are authorized to be appropriated to carry out this part 
such sums as are necessary for fiscal years 2010 through 2015.''.
    (b) Clerical Amendment.--The table of contents in section 2 of the 
Elementary and Secondary Education Act of 1965 is amended by adding 
after the item related to section 2441 the following:

     Part E--Recruitment, Training, and Retention of Teachers From 
                        Underrepresented Groups

Sec. 2501. Grant program.
Sec. 2502. Reports to Secretary.
Sec. 2503. Best practices information clearinghouse.
Sec. 2504. Definitions.
Sec. 2505. Authorization of appropriations.

A: Diverse Teachers Recruitment Act of 2010 - Amends the Elementary and Secondary Education Act of 1965 to direct the Secretary of Education to award competitive matching grants to local educational agencies (LEAs) or nonprofits, educational service agencies, institutions of higher education, or states that enter into partnerships with such LEAs, for recruiting, training, and retaining individuals from underrepresented groups as public elementary and secondary school teachers.

Gives priority to LEAs that serve the most high-need schools and those that serve schools with the highest percentages of minorities in their student bodies.

Requires the Secretary to evaluate the success of the grantees and compile a database of best practices for recruiting, training, and retaining individuals from underrepresented groups as public elementary and secondary school teachers.
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Helping Effective Antibiotics Last 
Act of 2015'' or the ``HEAL Act''.

SEC. 2. APPROVAL OF CERTAIN DRUGS FOR USE IN A WELL-DEFINED POPULATION 
              OF PATIENTS.

    (a) Approval of Certain Antibacterial.--Section 505 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355) is amended by adding at 
the end the following:
    ``(x) Approval of Certain Antibacterial Drugs for Use in a Well-
Defined Population of Patients.--
            ``(1) Unmet medical need defined.--In this subsection, the 
        term `unmet medical need' means that the antibacterial drug 
        involved--
                    ``(A) has improved efficacy, as demonstrated in 
                adequate, well-controlled studies in humans, for 
                specific diseases or conditions, where current 
                therapies have been shown to be less effective;
                    ``(B) has clinically meaningful decreased harms, 
                demonstrated in adequate, well-controlled studies in 
                humans, for diseases or conditions, where current 
                therapies have unacceptable adverse effects; or
                    ``(C) has improved convenience, as demonstrated in 
                adequate, well-controlled studies in humans, where 
                improved convenience results in improved effectiveness 
                or decreased harms.
            ``(2) Approval.--Upon receipt of an application under 
        subsection (b) for an antibacterial drug that is intended to 
        treat a serious or life-threatening disease or condition, 
        irrespective of whether the drug is intended to address an 
        unmet medical need, the Secretary--
                    ``(A) may approve the drug under subsection (c) 
                only for treating a well-defined population of 
                patients, and based upon the results of clinical trials 
                inclusive of human subjects representative of such 
                well-defined population;
                    ``(B) in determining whether to grant such 
                approval, shall rely on superior outcomes over 
                available therapies based on direct measures of patient 
                benefits, as demonstrated in adequate, well-controlled 
                studies in the well-defined patient population, such 
                as--
                            ``(i) decreased mortality;
                            ``(ii) irreversible morbidity; or
                            ``(iii) validated surrogate endpoints that 
                        reflect mortality or irreversible morbidity; 
                        and
                    ``(C) shall require the labeling of drugs approved 
                pursuant to this subsection to prominently include in 
                the prescribing information required by section 201.57 
                of title 21, Code of Federal Regulations (or any 
                successor regulation)--
                            ``(i) the population of patients with 
                        respect to which the added benefit over 
                        available therapies is expected as studied in 
                        adequate, well-controlled studies that form the 
                        basis for approval; and
                            ``(ii) the method for identifying members 
                        of that population.
            ``(3) Risk evaluation and mitigation strategy.--The 
        Secretary--
                    ``(A) shall require a risk evaluation and 
                mitigation strategy (REMS) under section 505-1 for each 
                drug approved under this subsection; and
                    ``(B) may include in any such strategy additional 
                elements to assure the safe use of the drug under 
                subsections (e) and (f) of section 505-1.
            ``(4) Rule of construction.--Nothing in this subsection 
        shall be construed to alter the standards of evidence under 
        subsection (c) or (d) (including the substantial evidence 
        standard in subsection (d)). Subsections (c) and (d) and such 
        standards of evidence apply to the review and approval of drugs 
        under this subsection, including whether a drug is safe and 
        effective. Nothing in this subsection shall be construed to 
        limit the authority of the Secretary to approve products 
        pursuant to this Act and the Public Health Service Act as 
        authorized prior to the date of enactment of this subsection.
            ``(5) Effective immediately.--The Secretary shall have the 
        authorities vested in the Secretary by this subsection 
        beginning on the date of enactment of this subsection, 
        irrespective of when and whether the Secretary promulgates 
        final regulations to carry out this subsection.''.
    (b) Licensure of Certain Biological Products.--Section 351(j) of 
the Public Health Service Act (42 U.S.C. 262(j)) is amended--
            (1) by striking ``(j)'' and inserting ``(j)(1)'';
            (2) by inserting ``505(x),'' after ``505(p),''; and
            (3) by adding at the end the following:
    ``(2) In applying section 505(x) of the Federal Food, Drug, and 
Cosmetic Act to the licensure of biological products under this 
section--
            ``(A) references to an antibacterial drug with added 
        benefits over available therapies for a well-defined population 
        that is intended to treat a serious or life-threatening disease 
        or condition shall be construed to refer to biological products 
        with added benefits over available therapies for a well-defined 
        population intended to treat a bacterial infection associated 
        with a serious or life-threatening disease; and
            ``(B) references to an application submitted under section 
        505(b) of such Act and to approval of a drug under section 
        505(c) of such Act shall be construed to refer to an 
        application submitted under subsection (a) of this section and 
        to licensure of a biological product under such subsection (a), 
        respectively.''.
    (c) Monitoring.--Title III of the Public Health Service Act is 
amended by inserting after section 317T (42 U.S.C. 247b-22) the 
following:

``SEC. 317U. MONITORING OF ANTIBACTERIAL DRUG USE, PATIENT OUTCOMES, 
              AND RESISTANCE.

    ``(a) Monitoring.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall use the National 
Healthcare Safety Network or another appropriate monitoring system to 
monitor--
            ``(1) changes in patient outcomes such as mortality and 
        irreversible morbidity causally related to antibacterial 
        resistance; and
            ``(2) changes in bacterial resistance to drugs in relation 
        to patient outcomes.
    ``(b) Public Availability of Data.--The Secretary, acting through 
the Director of the Centers for Disease Control and Prevention, shall 
make the data derived from monitoring under this section publicly 
available for the purposes of--
            ``(1) improving the monitoring of important trends in 
        patient outcomes in relation to antibacterial resistance; and
            ``(2) ensuring appropriate stewardship of antibacterial 
        drugs, including those receiving approval or licensure for a 
        well-defined population pursuant to section 505(x) of the 
        Federal Food, Drug, and Cosmetic Act.''.

SEC. 3. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROBIAL 
              ORGANISMS.

    (a) In General.--Section 511 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360a) is amended to read as follows:

``SEC. 511. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROBIAL 
              ORGANISMS.

    ``(a) In General.--The Secretary shall--
            ``(1) identify upon approval or licensing of antibacterial 
        drugs (including biological products intended to treat a 
        bacterial infection and other types of antimicrobial drugs, as 
        deemed appropriate by the Secretary), including qualified 
        infectious disease products, susceptibility test interpretive 
        criteria for such drugs based upon patient outcomes of 
        mortality and morbidity from adequate and well-controlled 
        studies and such other confirmatory evidence as the Secretary 
        deems necessary; and
            ``(2) update, consistent with subsection (b), such criteria 
        as needed based upon scientific evidence of changes in patient 
        outcomes.
    ``(b) Responding to Changes in Patient Outcomes To Evaluate 
Susceptibility Test Interpretive Criteria.--
            ``(1) In general.--As needed based on evidence related to 
        changes in patient outcomes, the Secretary shall--
                    ``(A) evaluate any new scientific studies on 
                changes in patient outcomes in relation to 
                susceptibility test interpretive criteria; and
                    ``(B) publish on the public Website of the Food and 
                Drug Administration a notice--
                            ``(i) presenting suggested new or updated 
                        interpretive criteria; and
                            ``(ii) if needed, hold a public advisory 
                        committee to discuss scientific evidence 
                        related to changes in interpretative criteria.
            ``(2) Annual compilation of notices.--Each year, the 
        Secretary shall compile the notices published under paragraph 
        (1)(B) noting any changes from prior notices and publish such 
        compilation in the Federal Register.
    ``(c) Definition.--In this section, the term `susceptibility test 
interpretive criteria' means one or more specific values which 
characterize patient outcomes in relation to the degree to which 
bacteria or other microbes are more resistant to treatment as measured 
by patient outcomes.''.
    (b) Conforming Amendment.--Section 1111 of the Food and Drug 
Administration Amendments Act of 2007 (42 U.S.C. 247d-5a; relating to 
identification of clinically susceptible concentrations of 
antimicrobials) is repealed.
    (c) Report to Congress.--Not later than one year after the date of 
enactment of this Act, the Secretary of Health and Human Services shall 
submit to the Committee on Energy and Commerce of the House of 
Representatives and the Committee on Health, Education, Labor, and 
Pensions of the Senate a report on the progress made in implementing 
section 511 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360a), as amended by this section.

SEC. 4. REQUIRING DEMONSTRATION OF SUPERIOR OUTCOMES FOR QUALIFIED 
              INFECTIOUS DISEASE PRODUCTS TO RECEIVE AN EXTENDED 
              EXCLUSIVITY PERIOD.

    Section 505E(g) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355f(g)) is amended by striking ``means an antibacterial or 
antifungal drug for human use intended to treat'' and inserting ``means 
an antibacterial or antifungal drug for human use that is demonstrated 
to produce superior outcomes over available therapies, based on direct 
measures of patient benefits in clinical trials, and that is intended 
to treat''.

SEC. 5. GUIDANCE ON TARGET PRODUCT PROFILES.

    Not later than 18 months after the date of enactment of this Act, 
the Commissioner of Food and Drugs, in consultation with the 
Administrator of the Centers for Medicare & Medicaid Services, the 
Director of the Indian Health Service, the Secretary of Defense, and 
the Secretary of Veterans Affairs, shall issue guidance on the 
development of target product profiles for novel antibacterial drugs 
focused on public health priorities.

A: Helping Effective Antibiotics Last Act of 2015 or the HEAL Act This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to approve an antibacterial drug or biological product that is intended to treat a serious or life-threatening condition only for treating a well-defined population of patients. To be approved, the antibacterial product must produce superior outcomes over available therapies in the well-defined patient population. A product approved by this pathway must include in its prescribing information the population of patients expected to benefit from using the product and the method for identifying members of that population. The FDA must require each product to have a risk evaluation and mitigation strategy. The Centers for Disease Control and Prevention must monitor changes to bacterial drug resistance and changes to patient outcomes caused by bacterial drug resistance. Upon approval of antibacterial products, the FDA must identify susceptibility test interpretive criteria (the drug concentrations where a type of bacteria is categorized as susceptible, intermediate, or resistant) and update the criteria as needed based upon evidence of changes in patient outcomes.  To be eligible for an exclusivity period extension, a qualified infectious disease product must be demonstrated to produce superior outcomes over available therapies. The FDA must issue guidance on the development of target product profiles for antibacterial drugs.
****
Q: SECTION 1. DEFINITIONS.

    For purposes of this Act, the following definitions shall apply:
            (1) Administration.--The term ``Administration'' means the 
        Federal Aviation Administration.
            (2) Administrator.--The term ``Administrator'' means the 
        Administrator of the Federal Aviation Administration.
            (3) Air transportation.--The term ``air transportation'' 
        means foreign air transportation, interstate air 
        transportation, or the transportation of mail by aircraft.
            (4) Aircraft.--The term ``aircraft'' means any contrivance 
        invented, used, or designed to navigate, or fly in, the air.
            (5) Function.--The term ``function'' means any duty, 
        obligation, power, authority, responsibility, right, privilege, 
        activity, or program.
            (6) Office.--The term ``office'' includes any office, 
        administration, agency, institute, unit, organizational entity, 
        or component thereof.
            (7) Secretary.--The term ``Secretary'' means the Secretary 
        of Transportation.

SEC. 2. REORGANIZATION.

    (a) In General.--Not later than 180 days after the date of 
enactment of this Act, the Secretary, in consultation with the 
Administrator, shall reorganize the Federal Aviation Administration in 
accordance with this Act.
    (b) Transfer of Functions.--In carrying out the reorganization 
under this Act, the Secretary shall transfer to another office of the 
Department any function of the Administration that is not directly 
related to the promotion of air safety.
    (c) Use of Funds.--In carrying out the reorganization under this 
Act, the Secretary is authorized to use funds made available for the 
Administration for the functions transferred to other offices of the 
Department under subsection (b)(1) to carry out those functions.

SEC. 3. SAVINGS PROVISIONS.

    (a) Continuing Effect of Legal Documents.--Until modified, 
terminated, superseded, set aside, or revoked in accordance with law by 
the President, the Secretary or other authorized official, a court of 
competent jurisdiction, or by operation of law, all orders, 
determinations, rules, regulations, permits, agreements, grants, 
contracts, certificates, licenses, registrations, privileges, and other 
administrative actions shall continue if they are--
            (1) issued, made, granted, or allowed to become effective 
        by the President, any Federal agency or official thereof, or by 
        a court of competent jurisdiction, in the performance of 
        functions that are transferred under this Act; and
            (2) in effect on the date of enactment of this Act, or were 
        final before the date of enactment of this Act and are to 
        become effective on or after such date.
    (b) Proceedings Not Affected.--
            (1) In general.--The provisions of this Act shall not 
        affect any proceedings, including notices of proposed 
        rulemaking, or any application for any license, permit, or 
        financial assistance pending before the Federal Aviation 
        Administration on the date of enactment of this Act, and those 
        proceedings and applications shall be continued. Orders shall 
        be issued in such proceedings, appeals shall be taken 
        therefrom, and payments shall be made pursuant to such orders, 
        as if this title had not been enacted, and shall continue in 
        effect until modified, terminated, superseded, or revoked by a 
        duly authorized official, by a court of competent jurisdiction, 
        or by operation of law.
            (4) Rule of construction.--Nothing in this subsection may 
        be construed to prohibit the discontinuance or modification of 
        any proceeding referred to in paragraph (1) under the same 
        terms and conditions, and to the same extent, that such 
        proceeding could have been discontinued if this Act had not 
        been enacted.
    (c) Suits Not Affected.--The provisions of this Act shall not 
affect suits commenced before the date of enactment of this Act. In all 
such suits, proceedings shall be had, appeals taken, and judgments 
rendered in the same manner and with the same effect as if this Act had 
not been enacted.
    (d) Nonabatement of Actions.--No suit, action, or other proceeding 
commenced by or against the Federal Aviation Administration or by and 
against any individual in the official capacity of such individual as 
an officer of the Federal Aviation Administration, shall abate by 
reason of the enactment of this Act.
    (e) Administrative Actions Relating to Promulgation of 
Regulations.--Any administrative action relating to the preparation or 
promulgation of a regulation by the Federal Aviation Administration 
relating to a function transferred under this title may be continued by 
the Department with the same effect as if this title had not been 
enacted.

SEC. 4. REFERENCES.

    Reference in any other Federal law, Executive order, regulation, or 
any document relating to--
            (1) the Administrator, with regard to the functions 
        transferred under section 2, shall be deemed to refer to the 
        Secretary; and
            (2) the Administration, with regard to functions 
        transferred under section 2, shall be deemed to refer to the 
        Department.

SEC. 5. RECOMMENDED LEGISLATION.

    Not later than 180 days after the date of enactment of this Act, 
the Secretary shall prepare and submit to the Congress recommended 
legislation containing technical and conforming amendments (including 
amendments to subtitle VII of title 49, United States Code) to reflect 
the changes made by this Act.

A:
Directs the Secretary of Transportation to reorganize the Federal Aviation Administration (FAA) by transferring to another office of the Department of Transportation any function of the FAA that is not directly related to the promotion of air safety.
****